Vascular changes in hepatocellular carcinoma

Anatomical Record

Volumn 291, Issue 6, 2008, Pages 721-734

  Yang, Zhen Fan ^a   Poon, Ronnie T P ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Hepatocellular carcinoma; Neoangiogenesis; Vascular endothelial growth factor

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOPOIETIN; ANTISENSE OLIGONUCLEOTIDE; BEVACIZUMAB; BRAIN DERIVED NEUROTROPHIC FACTOR; CD31 ANTIGEN; CD34 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CYCLOOXYGENASE 2; DOXORUBICIN; ENDOSTATIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FINGOLIMOD; FUMAGILLOL CHLOROACETYLCARBAMATE; IODINATED POPPYSEED OIL; LAMININ; MESSENGER RNA; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; SECURIN; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VATALANIB; THYMIDINE PHOSPHORYLASE; VASCULOTROPIN A;

ADJUVANT THERAPY; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTIFICIAL EMBOLISM; CANCER GENE THERAPY; CARCINOGENESIS; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CELL TYPE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DRUG EFFICACY; ENZYME INHIBITION; HEMATOPOIETIC STEM CELL; HUMAN; LIVER BLOOD FLOW; LIVER CELL CARCINOMA; LIVER PARENCHYMA; LIVER SINUSOID; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; REVIEW; STELLATE CELL; VASCULAR DISEASE; ANIMAL; CANCER STEM CELL; ENDOTHELIUM CELL; LIVER TUMOR; MICROCIRCULATION; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANGIOPOIETINS; ANIMALS; CARCINOMA, HEPATOCELLULAR; ENDOTHELIAL CELLS; EPIDERMAL GROWTH FACTOR; HUMANS; LIVER NEOPLASMS; MICROCIRCULATION; NEOPLASTIC STEM CELLS; NEOVASCULARIZATION, PATHOLOGIC; THYMIDINE PHOSPHORYLASE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 45849135992     PISSN: 19328486     EISSN: 19328494     Source Type: Journal    
DOI: 10.1002/ar.20668     Document Type: Review

References (157)

1. Aghi M, Cohen KS, Klein RJ, Scadden DT, Chiocca EA. 2006. Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes. Cancer Res 66:9054-9064.
2. Ahmad S, Hewett PW, Wang P, Al-Ani B, Cudmore M, Fujisawa T, Haigh JJ, le Noble F, Wang L, Mukhopadhyay D, Ahmed A. 2006. Direct evidence for endothelial vascular endothelial growth factor receptor-1 function in nitric oxide-mediated angiogenesis. Circ Res 99:715-722.
3. Akiba J, Yano H, Ogasawara S, Higaki K, Kojiro M. 2001. Expression and function of interleukin-8 in human hepatocellular carcinoma. Int J Oncol 18:257-264.
4. Amin DN, Hida K, Bielenberg DR, Klagsbrun M. 2006. Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors. Cancer Res 66:2173-2180.
5. Ankoma-Sey V, Wang Y, Dai Z. 2000. Hypoxic stimulation of vascular endothelial growth factor expression in activated rat hepatic stellate cells. Hepatology 31:141-148.
6. Arii S, Yamaoka Y, Futagawa S, Inoue K, Kobayashi K, Kojiro M, Makuuchi M, Nakamura Y, Okita K, Yamada R. 2000. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology 32:1224-1229.
7. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M, Magner M, Isner JM. 1999. Bone marrow origin of endothelial cell progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 85:221-228.
8. Azenshtein E, Meshel T, Shina S, Barak N, Keydar I, Ben-Baruch A. 2005. The angiogenic factors CXCL8 and VEGF in breast cancer: regulation by an array of pro-malignancy factors. Cancer Lett 217:73-86.
9. Bertolini F, Shaked Y, Mancuso P, Kerbel RS. 2006. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer 6:835-845.
10. Borkham-Kamphorst E, van Roeyen CR, Ostendorf T, Floege J, Gressner AM, Weiskirchen R. 2007. Pro-fibrogenic potential of PDGF-D in liver fibrosis. J Hepatol 46:1064-1074.
11. Brown JM, Wilson WR. 2004. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4:437-447.
12. Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases. 2005. Management of hepatocellular carcinoma. Hepatology 42:1208-1236.
13. Cervello M, Montalto G. 2006. Cyclooxygenases in hepatocellular carcinoma. World J Gastroenterol 12:5113-5121.
14. Chen LT, Liu TW, Chao Y, Shiah HS, Chang JY, Juang SH, Chen SC, Chuang TR, Chin YH, Whang-Peng J. 2005. Alpha-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma. Aliment Pharmacol Ther 22:217-226.
15. Cheng AS, Chan HL, To KF, Leung WK, Chan KK, Liew CT, Sung JJ. 2004. Cyclooxygenase-2 pathway correlates with vascular endothelial growth factor expression and tumor angiogenesis in hepatitis B virus-associated hepatocellular carcinoma. Int J Oncol 24:853-860.
16. Chow NH, Hsu PI, Lin XZ, Yang HB, Chan SH, Cheng KS, Huang SM, Su IJ. 1997. Expression of vascular endothelial growth factor in normal liver and hepatocellular carcinoma: an immunohistochemical study. Hum Pathol 28:698-703.
17. Couvelard A, Scoazec JY, Dauge MC, Bringuier AF, Potet F, Feldmann G. 1996. Structural and functional differentiation of sinusoidal endothelial cells during liver organogenesis in humans. Blood 87:4568-4580.
18. De Palma M, Naldini L. 2006. Role of haematopoietic cells and endothelial progenitors in tumour angiogenesis. Biochim Biophys Acta 1766:159-166.
19. Deli G, Jin CH, Mu R, Yang S, Liang Y, Chen D, Makuuchi M. 2005. Immunohistochemical assessment of angiogenesis in hepatocellular carcinoma and surrounding cirrhotic liver tissues. World J Gastroenterol 11:960-963.
20. Dhar DK, Naora H, Yamanoi A, Ono T, Kohno H, Otani H, Nagasue N. 2002. Requisite role of VEGF receptors in angiogenesis of hepatocellular carcinoma: a comparison with angiopoietin/Tie pathway. Anticancer Res 22:379-386.
21. Dickson PV, Hamner JB, Streck CJ, Ng CY, McCarville MB, Calabrese C, Gilbertson RJ, Stewart CF, Wilson CM, Gaber MW, Pfeffer LM, Skapek SX, Nathwani AC, Davidoff AM. 2007. Continuous delivery of IFN-beta promotes sustained maturation of intratumoral vasculature. Mol Cancer Res 5:531-542.
22. El-Assal ON, Yamanoi A, Ono T, Kohno H, Nagasue N. 2001. The clinicopathological significance of heparanase and basic fibroblast growth factor expressions in hepatocellular carcinoma. Clin Cancer Res 7:1299-1305.
23. El-Serag HB, 2004. Hepatocellular carcinoma: recent trend in the United States. Gastroenterology 127:S27-S34.
24. Ezaki T, Ikegami T, Maeda T, Yamada T, Ishida T, Hashizume M, Maehara Y. 2005. Prognostic value of thymidine phosphorylase activity in liver tissue adjacent to hepatocellular carcinoma. Int J Clin Oncol 10:171-176.
25. Fanale MA, Younes A. 2007. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. Drugs 67:333-350.
26. Faouzi S, Lepreux S, Bedin C, Dubuisson L, Balabaud C, Bioulac-Sage P, Desmouliere A, Rosenbaum J. 1999. Activation of cultured rat hepatic stellate cells by tumoral hepatocytes. Lab Invest 79:485-493.
27. Favier B, Alam A, Barron P, Bonnin J, Laboudie P, Fons P, Mandron M, Herault JP, Neufeld G, Savi P, Herbert JM, Bono F. 2006. Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cell survival and migration. Blood 108:1243-1250.
28. Feng KK, Zhao HY, Qiu H, Liu JX, Chen J. 2005. Combined therapy with flk1-based DNA vaccine and interleukin-12 results in enhanced antiangiogenic and antitumor effects. Cancer Lett 221:41-47.
29. Fischer AN, Fuchs E, Mikula M, Huber H, Beug H, Mikulits W. 2007. PDGF essentially links TGF-beta signaling to nuclear beta-catenin accumulation in hepatocellular carcinoma progression. Oncogene 26:3395-3405.
30. Frachon S, Gouysse G, Dumortier J, Couvelard A, Nejjari M, Mion F, Berger F, Paliard P, Boillot O, Scoazec JY. 2001. Endothelial cell marker expression in dysplastic lesions of the liver: an immunohistochemical study. J Hepatol 34:850-857.
31. Fujii T, Nomoto S, Koshikawa K, Yatabe Y, Teshigawara O, Mori T, Inoue S, Takeda S, Nakao A. 2006. Overexpression of pituitary tumor transforming gene 1 in HCC is associated with angiogenesis and poor prognosis. Hepatology 43:1267-1275.
32. Fukasawa M, Matsushita A, Korc M. 2007. Neuropilin-1 interacts with integrin beta1 and modulates pancreatic cancer cell growth, survival and invasion. Cancer Biol Ther 6:1173-1180.
33. Gasparini G, Longo R, Fanelli M, Teicher BA. 2005. Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. J Clin Oncol 23:1295-1311.
34. Geerts AM, De Vriese AS, Vanheule E, Van Vlierberghe H, Mortier S, Cheung KJ, Demetter P, Lameire N, De Vos M, Colle I. 2006. Increased angiogenesis and permeability in the mesenteric microvasculature of rats with cirrhosis and portal hypertension: an in vivo study. Liver Int 26:889-898.
35. Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V, Ferrara N. 1998. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 273:30336-30343.
36. Gorrin-Rivas MJ, Arii S, Mori A, Takeda Y, Takeda Y, Mizumoto M, Furutani M, Imamura M. 2000. Implications of human macrophage metalloelastase and vascular endothelial growth factor gene expression in angiogenesis of hepatocellular carcinoma. Ann Surg 231:67-73.
37. Graepler F, Verbeek B, Graeter T, Smirnow I, Kong HL, Schuppan D, Bauer M, Vonthein R, Gregor M, Lauer UM. 2005. Combined endostatin/sFlt-1 antiangiogenic gene therapy is highly effective in a rat model of HCC. Hepatology 41:879-886.
38. Griffiths L, Stratford IJ. 1997. Platelet-derived endothelial cell growth factor thymidine phosphorylase in tumour growth and response to therapy. Br J Cancer 76:689-693.
39. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. 1995. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 332:1256-1261.
40. Guo L, Kuroda N, Toi M, Miyazaki E, Hayashi Y, Enzan H, Jin Y. 2001. Increased expression of platelet-derived endothelial cell growth factor in human hepatocellular carcinomas correlated with high Edmondson grades and portal vein tumor thrombosis. Oncol Rep 8:871-876.
41. Gwak GY, Yoon JH, Kim KM, Lee HS, Chung JW, Gores GJ. 2005. Hypoxia stimulates proliferation of human hepatoma cells through the induction of hexokinase II expression. J Hepatol 42:358-364.
42. Harris AL. 2002. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2:38-47.
43. Himeno H, Enzan H, Saibara T, Onishi S, Yamamoto Y. 1994. Hitherto unrecognized arterioles within hepatocellular carcinoma. J Pathol 174:217-222.
44. Hisai H, Kato J, Kobune M, Murakami T, Miyanishi K, Takahashi M. 2003. Increased expression of angiogenin in hepatocellular carcinoma in correlation with tumor vascularity. Clin Cancer Res 9:4852-4859.
45. Ho JW, Poon RT, Sun CK, Xue WC, Fan ST. 2005a. Clinicopathological and prognostic implications of endoglin (CD105) expression in hepatocellular carcinoma and its adjacent non-tumorous liver. World J Gastroenterol 11:176-181.
46. Ho JW, Man K, Sun CK, Lee TK, Poon RT, Fan ST. 2005b. Effects of a novel immunomodulating agent, FTY720, on tumor growth and angiogenesis in hepatocellular carcinoma. Mol Cancer Ther 4:1430-1438.
47. Ho JW, Pang RW, Lau C, Sun CK, Yu WC, Fan ST, Poon RT. 2006. Significance of circulating endothelial progenitor cells in hepatocellular carcinoma. Hepatology 44:836-843.
48. Hong TM, Chen YL, Wu YY, Yuan A, Chao YC, Chung YC, Wu MH, Yang SC, Pan SH, Shih JY, Chan WK, Yang PC. 2007. Targeting neuropilin 1 as an antitumor strategy in lung cancer. Clin Cancer Res 13:4759-4768.
49. Huang GW, Yang LY, Lu WQ. 2005. Expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in hepatocellular carcinoma: impact on neovascularization and survival. World J Gastroenterol 11:1705-1708.
50. Huwart L, Michoux N, Van Beers B. 2007. Magnetic resonance imaging of angiogenesis in tumors. J Radiol 88(Pt 1):331-338.
51. Iavarone M, Lampertico P, Iannuzzi F, Manenti E, Donato MF, Arosio E, Bertolini F, Primignani M, Sangiovanni A, Colombo M. 2007. Increased expression of vascular endothelial growth factor in small hepatocellular carcinoma. J Viral Hepat 14:133-139.
52. Ishikawa H, Nakao K, Matsumoto K, Ichikawa T, Hamasaki K, Nakata K. 2003. Antiangiogenic gene therapy for hepatocellular carcinoma using angiostatin gene. Hepatology 37:696-704.
53. Jin DK, Shido K, Kopp HG, Petit I, Shmelkov SV, Young LM, Hooper AT, Amano H, Avecilla ST, Heissig B, Hattori K, Zhang F, Hicklin DJ, Wu Y, Zhu Z, Dunn A, Salari H, Werb Z, Hackett NR, Crystal RG, Lyden D, Rafii S. 2006. Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nat Med 12:557-567.
54. Kang MA, Kim KY, Seol JY, Kim KC, Nam MJ. 2000. The growth inhibition of hepatoma by gene transfer of antisense vascular endothelial growth factor. J Gene Med 2:289-296.
55. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA, Zhu Z, Hicklin D, Wu Y, Port JL, Altorki N, Port ER, Ruggero D, Shmelkov SV, Jensen KK, Rafii S, Lyden D. 2005. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438:820-827.
56. Ker CG, Chen HY, Juan CC, Lo HW, Shen YY, Chen JS, Lee KT, Sheen PC. 1999. Role of angiogenesis in hepatitis and hepatocellular carcinoma. Hepatogastroenterology 46:646-650.
57. Kermani P, Rafii D, Jin DK, Whitlock P, Schaffer W, Chiang A, Vincent L, Friedrich M, Shido K, Hackett NR, Crystal RG, Rafii S, Hempstead BL. 2005. Neurotrophins promote revascularization by local recruitment of TrkB+ endothelial cells and systemic mobilization of hematopoietic progenitors. J Clin Invest 115:653-663.
58. Kim H, Li Q, Hempstead BL, Madri JA. 2004. Paracrine and autocrine functions of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in brain-derived endothelial cells. J Biol Chem 279:33538-33546.
59. Kim CK, Lim JH, Park CK, Choi D, Lim HK, Lee WJ. 2005. Neoangiogenesis and sinusoidal capillarization in hepatocellular carcinoma: correlation between dynamic CT and density of tumor microvessels. Radiology 237:529-534.
60. Kimura H, Nakajima T, Kagawa K, Deguchi T, Kakusui M, Katagishi T, Okanoue T, Kashima K, Ashihara T. 1998. Angiogenesis in hepatocellular carcinoma as evaluated by CD34 immunohistochemistry. Liver 18:14-19.
61. Kin M, Torimura T, Ueno T, Inuzuka S, Tanikawa K. 1994. Sinusoidal capillarization in small hepatocellular carcinoma. Pathol Int 44:771-778.
62. Kubo F, Ueno S, Hiwatashi K, Sakoda M, Kawaida K, Nuruki K, Aikou T. 2005. Interleukin 8 in human hepatocellular carcinoma correlates with cancer cell invasion of vessels but not with tumor angiogenesis. Ann Surg Oncol 12:800-807.
63. Lau CP, Poon RT, Cheung ST, Yu WC, Fan ST. 2006. SPARC and Hevin expression correlate with tumour angiogenesis in hepatocellular carcinoma. J Pathol 210:459-468.
64. Lee TK, Poon RT, Yuen AP, Ling MT, Wang XH, Wong YC, Guan XY, Man K, Tang ZY, Fan ST. 2006. Regulation of angiogenesis by Id-1 through hypoxia-inducible factor-1alpha-mediated vascular endothelial growth factor up-regulation in hepatocellular carcinoma. Clin Cancer Res 12:6910-6919.
65. Li M, Tang ZY, Zhou G, Lui YK, Ye SL. 1998. Significance of vascular endothelial growth factor mRNA expression in invasion and metastasis of hepatocellular carcinoma. J Exp Clin Cancer Res 17:13-17.
66. Li B, Sharpe EE, Maupin AB, Teleron AA, Pyle AL, Carmeliet P, Young PP. 2006. VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization. FASEB J 20:1495-1497.
67. Liu H, Peng CH, Liu YB, Wu YL, Zhao ZM, Wang Y, Han BS. 2005. Inhibitory effect of adeno-associated virus-mediated gene transfer of human endostatin on hepatocellular carcinoma. World J Gastroenterol 11:3331-3334.
68. Liu Y, Poon RT, Li Q, Kok TW, Lau C, Fan ST. 2005. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res 65:3691-3699.
69. Llovet JM, Fuster J, Bruix J. 1999. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 30:1434-1440.
70. Llovet JM, Burroughs A, Bruix J. 2003. Hepatocellular carcinoma. Lancet 362:1907-1917.
71. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J. 2002. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164-1171.
72. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, Chadburn A, Heissig B, Marks W, Witte L, Wu Y, Hicklin D, Zhu Z, Hackett NR, Crystal RG, Moore MA, Hajjar KA, Manova K, Benezra R, Rafii S. 2001. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7:1194-1201.
73. Masood R, Cai J, Zheng T, Smith DL, Hinton DR, Gill PS. 2001. Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood 98:1904-1913.
74. Matsui O. 2001. Analysis of intranodular hemodynamics of dysplastic nodules in cirrhotic livers. Radiology 218:603-605.
75. McMahon BJ. 2005. Epidemiology and natural history of hepatitis B. Semin Liver Dis 25:3-8.
76. Medina J, Sanz-Cameno P, Garcia-Buey L, Martin-Vilchez S, Lopez-Cabrera M, Moreno-Otero R. 2005. Evidence of angiogenesis in primary biliary cirrhosis: an immunohistochemical descriptive study. J Hepatol 42:124-131.
77. Mise M, Arii H, Higashituji M, Furutani M, Niwano M, Harada T, Ishigami S, Toda Y, Nakayama H, Fukumoto M, Fujita J, Imamura M. 1996. Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor. Hepatology 23:455-464.
78. Mitsuhashi N, Shimizu H, Ohtsuka M, Wakabayashi Y, Ito H, Kimura F, Yoshidome H, Kato A, Nukui Y, Miyazaki M. 2003. Angiopoietins and Tie-2 expression in angiogenesis and proliferation of human hepatocellular carcinoma. Hepatology 37:1105-1113.
79. Moon WS, Park HS, Yu KH, Park MY, Kim KR, Jang K-Y, Kim JS, Cho BH. 2006. Expression of betacellulin and epidermal growth factor receptor in hepatocellular carcinoma: implications for angiogenesis. Hum Pathol 37:1324-1332.
80. Morinaga S, Yamamoto Y, Noguchi Y, Imada T, Rino Y, Akaike M, Sugimasa Y, Takemiya S, Takanashi Y. 2003. Platelet-derived endothelial cell growth factor (PD-ECGF) is up-regulated in human hepatocellular carcinoma (HCC) and the corresponding hepatitis liver. Hepatogastroenterology 50:1521-1526.
81. Musso O, Theret N, Heljasvaara R, Rehn M, Turlin B, Campion JP, Pihlajaniemi T, Clement B. 2001. Tumor hepatocytes and basement membrane-producing cells specifically express two different forms of the endostatin precursor, collagen XVIII, in human liver cancers. Hepatológy 33:868-876.
82. Nakamura K, Martin KC, Jackson JK, Beppu K, Woo CW, Thiele CJ. 2006. Brain-deiived neurotrophic factor activation of TrkB induces vascular endothelial growth factor expression via hypoxia-inducible factor-1alpha in neuroblastoma cells. Cancer Res 66:4249-4255.
83. Ng IO, Poon RT, Lee JM, Fan ST, Ng M, Tso WK. 2001. Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma. Am J Clin Pathol 116:838-845.
84. Novo E, Cannito S, Zamara E, Valfre di Bonzo L, Caligiuri A, Cravanzola C, Compagnone A, Colombatto S, Marra F, Pinzani M, Parola M. 2007. Proangiogenic cytokines as hypoxia-dependent factors stimulating migration of human hepatic stellate cells. Am J Pathol 170:1942-1953.
85. Olaso E, Salado C, Egilegor E, Gutierrez V, Santisteban A, Sancho-Bru P, Friedman SL, Vidal-Vanaclocha F. 2003. Proangiogenic role of tumor-activated hepatic stellate cells in experimental melanoma metastasis. Hepatology 37:674-685.
86. Pang R, Poon RT. 2006. Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Cancer Lett 242:151-167.
87. Park YN, Yang CP, Cubukcu O, Thung SN, Theise ND. 1997. Hepatic stellate cell activation in dysplastic nodules: evidence for an alternate hypothesis concerning human hepatocarcinogenesis. Liver 17:271-274.
88. Park YN, Yang CP, Fernandez GJ, Cubukcu O, Thung SN, Theise ND. 1998. Neoangiogenesis and sinusoidal "capillarization" in dysplastic nodules of the liver. Am J Surg Pathol 22:656-662.
89. Park YN, Kim YB, Yang KM, Park C. 2000, Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis. Arch Pathol Lab Med 124:1061-1065.
90. Patt YZ, Hassan MM, Lozano RD, Nooks AK, Schnirer II, Zeldis JB, Abbruzzese JL, Brown TD. 2005. Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial. Cancer 103:749-755.
91. Peters BA, Diaz LA, Polyak K, Meszler L, Romans K, Guinan EC, Antin JH, Myerson D, Hamilton SR, Vogelstein B, Kinzler KW, Lengauer C. 2005. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med 11:261-262.
92. Poon RT, Fan ST, Wong J. 2001. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 19:1207-1225.
93. Poon RT, Ng IO, Lau C, Yu WC, Yang ZF, Fan ST, Wong J. 2002. Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. J Clin Oncol 20:1775-1785.
94. Poon RT, Lau CP, Cheung ST, Yu WC, Fan ST. 2003a. Quantitative correlation of serum levels and tumor expression of vascular endothelial growth factor in patients with hepatocellular carcinoma. Cancer Res 63:3121-3126.
95. Poon RT, Lau CP, Ho J, Yu WC, Fan ST, Wong J. 2003b. Tissue factor expression correlates with tumor angiogenesis and invasiveness in human hepatocellular carcinoma. Clin Cancer Res 9:5339-5345.
96. Poon RT, Lau C, Yu WC, Fan ST, Wong J. 2004a. High serum levels of vascular endothelial growth factor predict poor response to transarterial chemoembolization in hepatocellular carcinoma: a prospective study. Oncol Rep 11:1077-1084.
97. Poon RT, Chung KK, Cheung ST, Lau C, Tong SW, Leung KL, Yu WC, Tuszynski GP, Fan ST. 2004b. Clinical significance of thrombospondin 1 expression in hepatocellular carcinoma. Clin Cancer Res 10:4150-4157.
98. Poon RT, Lau C, Pang R, Ng KK, Yuen J, Fan ST. 2007. High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies. Ann Surg Oncol 14:1835-1845.
99. Qin LX, Tang ZY, Li XM, Bu W, Xia JL. 1999. Effect of antiangiogenic agents on experimental animal models of hepatocellular carcinoma. Ann Acad Med Singapore 28:147-151.
100. Raoul JL, Guyader D, Bretagne JF, Heautot JF, Duvauferrier R, Bourguet P, Bekhechi D, Deugnier YM, Gosselin M. 1997. Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology 26:1156-1161.
101. Ren Y, Tsui HT, Poon RT, Ng IO, Li Z, Chen Y, Jiang G, Lau C, Yu WC, Bacher M, Fan ST. 2003. Macrophage migration inhibitory factor: roles in regulating tumor cell migration and expression of angiogenic factors in hepatocellular carcinoma. Int J Cancer 107:22-29,
102. Riess DJ Jr, Stern DF. 1998. Specificity within the EGF family/ErbB receptor family signaling network. Bioessays 20:41-48.
103. Rolny C, Nilsson I, Magnusson P, Armulik A, Jakobsson L, Wentzel P, Lindblom P, Norlin J, Betsholtz C, Heuchel R, Welsh M, Claesson-Welsh L. 2006. Platelet-derived growth factor receptor-beta promotes early endothelial cell differentiation. Blood 108:1877-1886.
104. Ryschich E, Lizdenis P, Ittrich C, Benner A, Stahl S, Hamann A, Schmidt J, Knolle P, Arnold B, Hammerling GJ, Ganss R. 2006. Molecular fingerprinting and autocrine growth regulation of endothelial cells in a murine model of hepatocellular carcinoma. Cancer Res 66:198-211.
105. Salomon DS, Brandt R, Ciardiello F, Normanno N. 1995. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183-232.
106. Sano T, Kagawa M, Okuno M, Ishibashi N, Hashimoto M, Yamamoto M, Suzuki R, Kohno H, Matsushima-Nishiwaki R, Takano Y, Tsurumi H, Kojima S, Friedman SL, Moriwaki H, Tanaka T. 2005. Prevention of rat hepatocarcinogenesis by acyclic retinoid is accompanied by reduction in emergence of both TGF-alpha-expressing oval-like cells and activated hepatic stellate cells. Nutr Cancer 51:197-206.
107. Schaffner F, Poper H. 1963. Capillarization of hepatic sinusoids in man. Gastroenterology 44:239-242.
108. Schimanski CC, Bahre R, Gockel I, Muller A, Frerichs K, Horner V, Teufel A, Simiantonaki N, Biesterfeld S, Wehler T, Schuler M, Achenbach T, Junginger T, Galle PR, Moehler M. 2006. Dissemination of hepatocellular carcinoma is mediated via chemokine receptor CXCR4. Br J Cancer 95:210-217.
109. Schmitt M, Horbach A, Kubitz R, Frilling A, Haussinger D. 2004. Disruption of hepatocellular tight junctions by vascular endothelial growth factor (VEGF): a novel mechanism for tumor invasion. J Hepatol 41:274-283.
110. Schweigerer L, Neufeld G, Friedman J, Abraham JA, Fiddes JC, Gospodarowicz D. 1987. Capillary endothelial cells express basic fibroblast growth factor, a mitogen that promotes their own growth. Nature 325:257-259.
111. Shaked Y, Ciarrocchi A, Franco M, Lee CR, Man S, Cheung AM, Hicklin DJ, Chaplin D, Foster FS, Benezra R, Kerbel RS. 2006. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 313:1785-1787.
112. Sheen IS, Jeng KS, Shih SC, Kao CR, Chang WH, Wang HY, Wang PC, Wang TE, Shyung LR, Chen CZ. 2005. Clinical significance of the expression of isoform 165 vascular endothelial growth factor mRNA in noncancerous liver remnants of patients with hepatocellular carcinoma. World J Gastroenterol 11:187-192.
113. Shi Q, Rafii S, Wu MH, Wijelath ES, Yu C, Ishida A, Fujita Y, Kothari S, Mohle R, Sauvage LR, Moore MA, Storb RF, Hammond WP. 1998. Evidence for circulating bone marrow-derived endothelial cells. Blood 92:362-367.
114. Shin EC, Choi YH, Kim JS, Kim SJ, Park JH. 2002. Expression patterns of cytokines and chemokines genes in human hepatoma cells. Yonsei Med J 43:657-664.
115. Staton CA, Kumar I, Reed MW, Brown NJ. 2007. Neuropilins in physiological and pathological angiogenesis. J Pathol 212:237-248.
116. Sugimachi K, Tanaka S, Taguchi K, Aishima S, Shimada M, Tsuneyoshi M. 2003. Angiopoietin switching regulates angiogenesis and progression of human hepatocellular carcinoma. J Clin Pathol 56:854-860.
117. Sun HC, Tang ZY. 2004. Angiogenesis in hepatocellular carcinoma: the retrospectives and perspectives. J Cancer Res Clin Oncol 130:307-319.
118. Sun HC, Tang ZY, Li XM, Zhou YN, Sun BR, Ma ZC. 1999. Microvessel density of hepatocellular carcinoma: its relationship with prognosis. Cancer Res Clin Oncol 125:419-426.
119. Sun MH, Han XC, Jia MK, Jiang WD, Wang M, Zhang H, Han G, Jiang Y. 2005. Expressions of inducible nitric oxide synthase and matrix metalloproteinase-9 and their effects on angiogenesis and progression of hepatocellular carcinoma. World J Gastroenterol 11:5931-5937.
120. Sun B, Zhang S, Zhang D, Du J, Guo H, Zhao X, Zhang W, Hao X. 2006. Vasculogenic mimicry is associated with high tumor grade, invasion and metastasis, and short survival in patients with hepatocellular carcinoma. Oncol Rep 16:693-698.
121. Sutton A, Friand V, Brule-Donneger S, Chaigneau T, Ziol M, Sainte-Catherine O, Poire A, Saffar L, Kraemer M, Vassy J, Nahon P, Salzmann JL, Gattegno L, Charnaux N. 2007. Stromal cell-derived factor-1/ chemokine (C-X-C motif) ligand 12 stimulates human hepatoma cell growth, migration, and invasion. Mol Cancer Res 5:21-33.
122. Tanaka S, Mori M, Sakamoto Y, Makuuchi M, Sugimachi K, Wands JR. 1999. Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. J Clin Invest 103:341-345.
123. Tanaka F, Otake Y, Yanagihara K, Kawano Y, Miyahara R, Li M, Yamada T, Hanaoka N, Inui K, Wada H. 2001. Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody. Clin Cancer Res 7:3410-3415.
124. Tanaka H, Yamamoto M, Hashimoto N, Miyakoshi M, Tamakawa S, Yoshie M, Tokusashi Y, Yokoyama K, Yaginuma Y, Ogawa K. 2006. Hypoxia-independent overexpression of hypoxia-inducible factor 1alpha as an early change in mouse hepatocarcinogenesis. Cancer Res 66:11263-11270.
125. Tang TC, Poon RT, Lau CP, Xie D, Fan ST. 2005. Tumor cyclooxygenase-2 levels correlate with tumor invasiveness in human hepatocellular carcinoma. World J Gastroenterol 11:1896-1902.
126. Tanigawa N, Lu C, Mitsui T, Miura S. 1997. Quantitation of sinusoid-like vessels in hepatocellular carcinoma: its clinical and prognostic significance. Hepatology 26:1216-1223.
127. Torimura T, Sata M, Ueno T, Kin M, Tsuji R, Suzaku K, Hashimoto O, Sugawara H, Tanikawa K. 1998. Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma. Hum Pathol 29:986-991.
128. Torimura T, Ueno T, Kin M, Harada R, Taniguchi E, Nakamura T, Sakata R, Hashimoto O, Sakamoto M, Kumashiro R, Sata M, Nakashima O, Yano H, Kojiro M. 2004. Overexpression of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma. J Hepatol 40:799-807.
129. Ueda K, Terada T, Nakanuma Y, Matsui O. 1992. Vascular supply in adenomatous hyperplasia of the liver and hepatocellular carcinoma: a morphometric study. Hum Pathol 23:619-626.
130. Ueda S, Basaki Y, Yoshie M, Ogawa K, Sakisaka S, Kuwano M, Ono M. 2006. PTEN/Akt signaling through epidermal growth factor receptor is prerequisite for angiogenesis by hepatocellular carcinoma cells that is susceptible to inhibition by gefitinib. Cancer Res 66:5346-5353.
131. Vogel C, Bauer A, Wiesnet M, Preissner KT, Schaper W, Marti HH, Fischer S. 2007. Flt-1, but not Flk-1 mediates hyperpermeability through activation of the PI3-K/Akt pathway. J Cell Physiol 212: 236-243.
132. von Marschall Z, Cramer T, Hocker M, Finkenzeller G, Wiedenmann B, Rosewicz S. 2001. Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinoma. Gut 48:87-96.
133. Wada H, Nagano H, Yamamoto H, Yang Y, Kondo M, Ota H, Nakamura M, Yoshioka S, Kato H, Damdinsuren B, Tang D, Marubashi S, Miyamoto A, Takeda Y, Umeshita K, Nakamori S, Sakon M, Dono K, Wakasa K, Monden M. 2006. Expression pattern of angiogenic factors and prognosis after hepatic resection in hepatocellular carcinoma: importance of angiopoietin-2 and hypoxia-induced factor-1 alpha. Liver Int 26:414-423.
134. Wang L, Tang ZY, Qin LX, Wu XF, Sun HC, Xue Q, Ye SL. 2000. High-dose and long-term therapy with interferon-alfa inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential. Hepatology 32:43-48.
135. Wang SN, Yeh YT, Yang SF, Chai CY, Lee KT. 2006. Potential role of leptin expression in hepatocellular carcinoma. J Clin Pathol 59:930-934.
136. Weigand M, Hantel P, Kreienberg R, Waltenberger J. 2005. Autocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primary breast cancer cultures in vitro. Angiogenesis 8:197-204.
137. Wu H, Feng G, Liang H, Zheng C, Li X. 2004. Vascular endothelial growth factor antisense oligodeoxynucleotides with lipiodol in arterial embolization of liver cancer in rats. World J Gastroenterol 10:813-818.
138. Xia JL, Yang BH, Tang ZY, Sun FX, Xue Q, Gao DM. 1997. Inhibitory effect of the angiogenesis inhibitor TNP-470 on tumor growth and metastasis in nude mice bearing human hepatocellular carcinoma. J Cancer Res Clin Oncol 123:383-387.
139. Yamamoto A, Dhar DK, El-Assal ON, Igarashi M, Tabara H, Nagasue N. 1998. Thymidine phosphorylase (platelet-derived endothelial cell growth factor), microvessel density and clinical outcome in hepatocellular carcinoma. J Hepatol 29:290-299.
140. Yamamoto T, Hirohashi K, Kaneda K, Ikebe T, Mikami S, Uenishi T, Kanazawa A, Takemura S, Shuto T, Tanaka H, Kubo S, Sakurai M, Kinoshita H. 2001. Relationship of the microvascular type to the tumor size, arterialization and dedifferentiation of human hepatocellular carcinoma. Jpn J Cancer Res 92:1207-1213.
141. Yang ZF, Poon RT, To J, Ho DW, Fan ST. 2004. The potential role of hypoxia inducible factor 1alpha in tumor progression after hypoxia and chemotherapy in hepatocellular carcinoma. Cancer Res 64:5496-5503.
142. Yang ZF, Ho DW, Lam CT, Luk JM, Lum CT, Yu WC, Poon RT, Fan ST. 2005. Identification of brain-derived neurotrophic factor as a novel functional protein in hepatocellular carcinoma. Cancer Res 65:219-225.
143. Yang LY, Lu WQ, Huang GW, Wang W. 2006. Correlation between CD105 expression and postoperative recurrence and metastasis of hepatocellular carcinoma. BMC Cancer 6:110.
144. Yang ZF, Poon RT, Liu Y, Lau CK, Tam KH, Lam CT, Fan ST. 2006. High doses of tyrosine kinase inhibitor PTK787 enhance the efficacy of ischemic hypoxia for the treatment of HCC: dual effects on cancer cell and angiogenesis. Mol Cancer Ther 5:2261-2270.
145. Yao Y, Pan Y, Chen J, Sun X, Qiu Y, Ding Y. 2007. Endoglin (CD105) expression in angiogenesis of primary hepatocellular carcinomas: analysis using tissue microarrays and comparisons with CD34 and VEGF. Ann Clin Lab Sci 37:39-48.
146. Yasuda S, Arii S, Mori A, Isobe N, Yang W, Oe H, Fujimoto A, Yonenaga Y, Sakashita H, Imamura M. 2004. Hexokinase II and VEGF expression in liver tumors: correlation with hypoxia-inducible factor 1 alpha and its significance. J Hepatol 40:117-123.
147. Yoo YG, Oh SH, Park ES, Cho H, Lee N, Park H, Kim DK, Yu DY, Seong JK, Lee MO. 2003. Hepatitis B virus X protein enhances transcriptional activity of hypoxia-inducible factor-1alpha through activation of mitogen-activated protein kinase pathway. J Biol Chem 278:39076-39084.
148. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Hicklin DJ, Wu Y, Yanase K, Namisaki T, Kitade M, Yamazaki M, Tsujinoue H, Masaki T, Fukui H. 2004. Halting the interaction between vascular endothelial growth factor and its receptors attenuates liver carcinogenesis in mice. Hepatology 39:1517-1524.
149. Yoshiji H, Kuriyama S, Noguchi R, Yoshii J, Ikenaka Y, Yanase K, Namisaki T, Kitade M, Uemura M, Masaki T, Fukui H. 2005. Angiopoietin 2 displays a vascular endothelial growth factor dependent synergistic effect in hepatocellular carcinoma development in mice. Gut 54:1768-1775.
150. Yu Q. 2005. The dynamic roles of angiopoietins in tumor angiogenesis. Future Oncol 1:475-484.
151. Yung YC, Cheshier S, Santarelli JG, Huang Z, Wagers A, Weissman I, Tse V. 2004. Incorporation of naive bone marrow derived cells into the vascular architecture of brain tumor. Microcirculation 11:699-708.
152. Zhang J, Wang WL, Li Q, Qiao Q. 2004. Expression of transforming growth factor-alpha and hepatitis B surface antigen in human hepatocellular carcinoma tissues and its significance. World J Gastroenterol 10:830-833.
153. Zhang T, Sun HC, Xu Y, Zhang KZ, Wang L, Qin LX, Wu WZ, Liu YK, Ye SL, Tang ZY. 2005. Overexpression of platelet-derived growth factor receptor alpha in endothelial cells of hepatocellular carcinoma associated with high metastatic potential. Clin Cancer Res 11(Pt 1):8557-8563.
154. Zhang ZL, Liu ZS, Sun Q. 2006. Expression of angiopoietins, Tie2 and vascular endothelial growth factor in angiogenesis and progression of hepatocellular carcinoma. World J Gastroenterol 12:4241-4245.
155. Zhao ZC, Zheng SS, Wan YL, Jia CK, Xie HY. 2003. The molecular mechanism underlying angiogenesis in hepatocellular carcinoma: the imbalance activation of signaling pathways. Hepatobiliary Pancreat Dis Int 2:529-536.
156. Zhou J, Tang ZY, Fan J, Wu ZQ, Li XM, Liu YK, Liu F, Sun HC, Ye SL. 2000. Expression of platelet-derived endothelial cell growth factor and vascular endothelial growth factor in hepatocellular carcinoma and portal vein tumor thrombus. J Cancer Res Clin Oncol 126:57-61.
157. Zhu AX, Blaszkowsky LS, Ryan DP, Clark JW, Muzikansky A, Horgan K, Sheehan S, Hale KE, Enzinger PC, Bhargava P, Stuart K. 2006. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 24:1898-1903.